Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Tuesday, the FDA verbally notified RAPT Therapeutics Inc (NASDAQ:RAPT) that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma.
The shares closed at $6.87 on Tuesday, sharply down from $25.97 at Friday’s close.
Wednesday, RAPT Therapeutics shares are trading higher on a rebound amid increased volatility in the stock, which sold off yesterday after the clinical trial setback.
RAPT shares are trading on a strong session volume of 11.01 million, compared to an average volume of 628.843K, as per data from Benzinga Pro.
However, certain analysts downgraded RAPT Therapeutics after the trial setback:
HC Wainwright downgraded RAPT Therapeutics from Buy to Neutral, noting that the FDA clinical hold creates zelnecirnon uncertainty.
Leerink Partners downgraded RAPT Therapeutics from Outperform to Market Perform and announced a price target of $10.
Cantor Fitzgerald downgraded RAPT Therapeutics from Overweight to Neutral.
Barclays maintained the Overweight rating on the stock but lowered the price target from $35 to $13.
JP Morgan downgraded RAPT Therapeutics from Overweight to Neutral and cut the price target from $35 to $15.
Price Action: RAPT shares are up 27.9% at $8.79 on the last check Wednesday.
Darko Stojanovic from Pixabay
Posted In: RAPT